The Bitter End: The Ubiquitin-Proteasome System and Cardiac Dysfunction

Many elements contribute to congestive heart failure: changes in perfusion, hemodynamic stresses, alterations in calcium metabolism, and dysregulation of cell signaling pathways. Intervention in these processes forms the basis for current heart failure therapies. Nevertheless, heart failure is primarily a disease of wear and tear; despite everything we know about cardiac physiology and the clinical manifestations of heart failure, only in rare instances does therapy for heart failure normalize cardiac function. Proteins are especially prone to the forces of wear and tear in the heart because they are the primary mechanisms for stress sensing and force generation. Recent evidence supports a role for protein damage and impaired clearance of damaged proteins in the pathophysiology of human heart failure syndromes. The process of monitoring and protecting cardiac cells from accumulation of damaged proteins is known as protein quality control, and the molecular chaperone and ubiquitin-proteasome systems are the primary effectors of this process. Insights from protein quality-control strategies may lead to new concepts about prevention and treatment of human heart failure. This review provides a general overview of these pathways and their known and postulated roles in human heart failure syndromes, with a focus on providing a clinically oriented understanding of these fundamental mechanisms.

[1]  S. Vatner,et al.  Activation of the Cardiac Proteasome During Pressure Overload Promotes Ventricular Hypertrophy , 2006, Circulation.

[2]  C. Patterson,et al.  Into the heart: the emerging role of the ubiquitin-proteasome system. , 2006, Journal of molecular and cellular cardiology.

[3]  D. Castrillon,et al.  Foxo Transcription Factors Blunt Cardiac Hypertrophy by Inhibiting Calcineurin Signaling , 2006, Circulation.

[4]  Peipei Ping,et al.  Regulation of Murine Cardiac 20S Proteasomes: Role of Associating Partners , 2006, Circulation research.

[5]  P. Ping,et al.  Mapping the Murine Cardiac 26S Proteasome Complexes , 2006, Circulation research.

[6]  C. Fan,et al.  Sequential Quality-Control Checkpoints Triage Misfolded Cystic Fibrosis Transmembrane Conductance Regulator , 2006, Cell.

[7]  E. Masliah,et al.  Prion-Induced Amyloid Heart Disease with High Blood Infectivity in Transgenic Mice , 2006, Science.

[8]  Hui-Yan Li,et al.  MDM2 interacts with and downregulates a sarcomeric protein, TCAP. , 2006, Biochemical and biophysical research communications.

[9]  P. Razeghi,et al.  Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. , 2006, Biochemical and biophysical research communications.

[10]  Jinbao Liu,et al.  Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. , 2006, Journal of molecular and cellular cardiology.

[11]  Holly McDonough,et al.  CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70 , 2006, Nature.

[12]  M. Hori,et al.  Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. , 2006, Biochemical and biophysical research communications.

[13]  L. Qin,et al.  Differential Regulation of Cardiomyocyte Survival and Hypertrophy by MDM2, an E3 Ubiquitin Ligase* , 2006, Journal of Biological Chemistry.

[14]  Holly McDonough,et al.  Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP , 2005, The Journal of cell biology.

[15]  E. Murphy,et al.  Mitochondrial Dysfunction and Apoptosis Underlie the Pathogenic Process in α-B-Crystallin Desmin-Related Cardiomyopathy , 2005, Circulation.

[16]  R. Kayed,et al.  Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Thomas Sejersen,et al.  The Kinase Domain of Titin Controls Muscle Gene Expression and Protein Turnover , 2005, Science.

[18]  L. Michael,et al.  CHIP, a cochaperone/ubiquitin ligase that regulates protein quality control, is required for maximal cardioprotection after myocardial infarction in mice. , 2005, American journal of physiology. Heart and circulatory physiology.

[19]  K. Lindenberg,et al.  Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. , 2005, Cardiovascular research.

[20]  E. Bennett,et al.  Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. , 2005, Molecular cell.

[21]  Holly McDonough,et al.  Muscle ring finger protein-1 inhibits PKCε activation and prevents cardiomyocyte hypertrophy , 2004, The Journal of cell biology.

[22]  Cam Patterson,et al.  Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[24]  G. Yancopoulos,et al.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.

[25]  Yi-Ping Li,et al.  Atrophic Remodeling of the Heart In Vivo Simultaneously Activates Pathways of Protein Synthesis and Degradation , 2003, Circulation.

[26]  V. Godfrey,et al.  CHIP activates HSF1 and confers protection against apoptosis and cellular stress , 2003, The EMBO journal.

[27]  J. Schaper,et al.  Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms , 2003, Circulation.

[28]  Michael J Dunn,et al.  Hyperubiquitination of proteins in dilated cardiomyopathy , 2003, Proteomics.

[29]  Cam Patterson,et al.  Welcome to the machine: a cardiologist's introduction to protein folding and degradation. , 2002, Circulation.

[30]  K. Fischbeck,et al.  Toxic Proteins in Neurodegenerative Disease , 2002, Science.

[31]  P. Kloetzel,et al.  Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. , 2002, Biochemical and biophysical research communications.

[32]  Cam Patterson,et al.  A New Gun in Town: The U Box Is a Ubiquitin Ligase Domain , 2002, Science's STKE.

[33]  B. Friguet,et al.  Age-dependent declines in proteasome activity in the heart. , 2002, Archives of biochemistry and biophysics.

[34]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Cyr,et al.  CHIP Is a U-box-dependent E3 Ubiquitin Ligase , 2001, The Journal of Biological Chemistry.

[36]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[37]  T. Hewett,et al.  Expression of R120G–αB-Crystallin Causes Aberrant Desmin and αB-Crystallin Aggregation and Cardiomyopathy in Mice , 2001 .

[38]  G. Dorn,et al.  Mouse Model of Desmin-Related Cardiomyopathy , 2001, Circulation.

[39]  K. Pelin,et al.  Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. , 2001, Journal of molecular biology.

[40]  E. Olson,et al.  Regulation of Microtubule Dynamics and Myogenic Differentiation by Murf, a Striated Muscle Ring-Finger Protein , 2000, The Journal of cell biology.

[41]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[42]  M. Dalakas,et al.  Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. , 2000, The New England journal of medicine.

[43]  S. Gottesman,et al.  Posttranslational quality control: folding, refolding, and degrading proteins. , 1999, Science.

[44]  S. Jentsch,et al.  A Novel Ubiquitination Factor, E4, Is Involved in Multiubiquitin Chain Assembly , 1999, Cell.

[45]  M. Prevost,et al.  A missense mutation in the αB-crystallin chaperone gene causes a desmin-related myopathy , 1998, Nature Genetics.

[46]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[47]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[48]  R. Mestril,et al.  Expression of inducible stress protein 70 in rat heart myogenic cells confers protection against simulated ischemia-induced injury. , 1994, The Journal of clinical investigation.

[49]  C. Delcayre,et al.  Storage of phosphorylated desmin in a familial myopathy , 1988, FEBS letters.

[50]  A. Samarel,et al.  Protein synthesis and degradation during starvation-induced cardiac atrophy in rabbits. , 1987, Circulation research.

[51]  T. Hewett,et al.  Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. , 2001, Circulation research.

[52]  M J Dunn,et al.  Bovine dilated cardiomyopathy: Proteomic analysis of an animal model of human dilated cardiomyopathy , 1999, Electrophoresis.